[go: up one dir, main page]

WO2010041647A1 - Agent d'amélioration de l'endurance physique, agent antifatigue ou agent de récupération de la fatigue comportant une composition d'acide aminé en tant qu'ingrédient actif - Google Patents

Agent d'amélioration de l'endurance physique, agent antifatigue ou agent de récupération de la fatigue comportant une composition d'acide aminé en tant qu'ingrédient actif Download PDF

Info

Publication number
WO2010041647A1
WO2010041647A1 PCT/JP2009/067387 JP2009067387W WO2010041647A1 WO 2010041647 A1 WO2010041647 A1 WO 2010041647A1 JP 2009067387 W JP2009067387 W JP 2009067387W WO 2010041647 A1 WO2010041647 A1 WO 2010041647A1
Authority
WO
WIPO (PCT)
Prior art keywords
mol
fatigue
amino acid
tyrosine
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2009/067387
Other languages
English (en)
Japanese (ja)
Inventor
宏行 有田
雅子 常松
浩 越膳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Dairies Corp
Original Assignee
Meiji Dairies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Dairies Corp filed Critical Meiji Dairies Corp
Priority to CN2009801394775A priority Critical patent/CN102170876B/zh
Priority to HK12100054.9A priority patent/HK1159507B/xx
Priority to JP2010532916A priority patent/JPWO2010041647A1/ja
Publication of WO2010041647A1 publication Critical patent/WO2010041647A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention belongs to the technical field of compositions for improving endurance, preventing fatigue, or recovering from fatigue. More specifically, the present invention relates to an amino acid composition that improves endurance, prevents fatigue, or recovers fatigue.
  • Non-patent Document 1 a protein having a specific molecular weight (57 KDa) isolated from royal jelly has an aerobic exercise promoting component effective for improving cardiopulmonary function and endurance (Patent Document 1).
  • Patent Document 2 cacao nibs and / or processed products thereof (Patent Document 2), food compositions containing Coenzyme Q10 and (-)-hydroxycitric acid (Patent Document 3), compositions containing thioctic acid or thioctic acid and creatine (Patent Documents) 4) is known as an active ingredient for improving endurance. And it is supposed that the composition containing panthetins and branched amino acids has an effect of preventing endurance reduction (Patent Document 5).
  • a wasp-derived amino acid composition is used as a muscle strength-retaining agent, a nutritional tonic, an infusion solution, a nutritional supplement, a fatigue recovery agent, or a lactic acid production regulator (Patent Document 6).
  • Patent Document 7 describes a fatigue recovery composition containing aspartic acid as an active ingredient.
  • JP 2008-105954 describes an agent for promoting differentiation of bone marrow erythrocyte progenitor cells and an anemia treatment agent containing at least one of alanine, serine, glutamine, tyrosine and asparagine as an active ingredient.
  • JP 2008-105954 Patent Document 8 describes an agent for promoting differentiation of bone marrow erythrocyte progenitor cells and an anemia treatment agent containing at least one of alanine, serine, glutamine, tyrosine and asparagine as an active ingredient.
  • Patent Document 9 describes a composition for suppressing fat accumulation containing threonine or leucine as an active ingredient. JP 2001-172195 A JP 2006-282576 A JP 2004-81010 A JP 2007-131609 JP 2006-16358 Patent No.2518692 WO2003-011056 JP2008-105954 JP2008-081498 Journal of Japanese Society of Hemorheology, Vol. 6, No. 2 (2003) 83-88
  • amino acid compositions Various activities have been known in the past for amino acid compositions, but the optimal composition for improving endurance, preventing fatigue or recovering from fatigue has not been known yet, and for example, amino acid compositions derived from wasps It has not been specified which amino acid in the amino acid composition (mixture) is particularly effective for improving endurance and what concentration of amino acid is effective for improving endurance.
  • amino acid compositions are often used as, for example, liquid beverages or liquids, but due to differences in solubility for each amino acid, there are also components that are problematic to dissolve in amino acid compositions. For example, since tyrosine has low solubility in water, it is desired to reduce its use amount as much as possible.
  • the present invention aims to identify amino acid components and concentrations effective for improving endurance, preventing fatigue, or recovering from fatigue in the amino acid composition, and reducing amino acid components with low solubility.
  • the inventors of the present application have long studied various actions of the amino acid composition derived from wasps.
  • the present invention provides an amino acid component that improves endurance, prevents fatigue, or restores fatigue.
  • the change in body weight during the experimental period (Value are mean ⁇ ⁇ ⁇ SE) is shown. There was no significant difference in the weight of each group.
  • the effect on swimming time by single administration (Value are mean ⁇ SE) is shown.
  • the effect on swimming time by repeated administration (Value are mean ⁇ SE) is shown. *: P ⁇ 0.05, **: p ⁇ 0.01 vs. control.
  • the measured value of glucose (Value are mean ⁇ SE) in blood is shown.
  • the measured value of lactic acid (Value are mean ⁇ SE) in blood is shown.
  • *: P ⁇ 0.05 vs. control The measured value of free fatty acid (Value are mean ⁇ SE) in blood is shown.
  • the measured value of hydroxyl butyric acid (Value are mean ⁇ SE) is shown. *: P ⁇ 0.05 vs. control.
  • the measured value of creatine kinase (Value are mean ⁇ SE) is shown.
  • the measured value of glycogen (Value are mean ⁇ SE) of liver and muscle (hyfuku muscle) is shown.
  • the measured value of the fat tissue weight (Value are mean ⁇ ⁇ SE) around the testis is shown. **: p ⁇ 0.01 vs. control.
  • the measured value of the muscle weight (Value are mean ⁇ SE) of the gastrocnemius and quadriceps is shown. *: P ⁇ 0.05 vs. control.
  • the present invention includes an amino acid composition for improving endurance and an endurance improver comprising the amino acid composition as an active ingredient.
  • the amino acid composition for improving endurance of the present invention may be an edible, medical or health food amino acid composition.
  • the endurance improver of the present invention is effective in improving both local endurance and whole body endurance.
  • VO 2 max maximum oxygen intake
  • gas analysis This can be measured by sampling directly from a moving subject via a gas mask.
  • the present invention provides an amino acid composition that can be used as an anti-fatigue agent by taking (administering) in advance when it is desired to prevent fatigue, and by taking (administering) after the fact when fatigue is felt. Also included are amino acid compositions that can be used as fatigue recovery agents.
  • the present invention includes an endurance improver, a fatigue inhibitor, and a fatigue recovery agent characterized by containing at least tyrosine as an active ingredient. More specifically, the present invention relates to an endurance improver comprising only tyrosine, an anti-fatigue agent, and a fatigue recovery agent, and an endurance improvement agent containing an amino acid other than tyrosine, an anti-fatigue agent, and a fatigue recovery agent. Include.
  • amino acids other than tyrosine include branched chain amino acids (BCAA), and specifically include the group consisting of valine, leucine, isoleucine, arginine, glutamic acid, aspartic acid, alanine, proline, lysine, and phenylalanine. Any one or more amino acids selected from can be used.
  • BCAA branched chain amino acids
  • an amino acid composition comprising only tyrosine, valine, leucine, isoleucine, arginine, glutamic acid, aspartic acid, alanine, proline, lysine, and phenylalanine as an active ingredient, Strength improver, fatigue inhibitor, and / or fatigue recovery agent, and (2) tyrosine, valine, leucine, isoleucine, arginine, glutamic acid, aspartic acid, alanine, proline, lysine, phenylalanine, threonine, glycine, serine, methionine , Endurance improver, anti-fatigue agent, and / or fatigue recovery agent comprising an amino acid composition consisting of only histidine and tryptophan as an active ingredient.
  • the present invention also includes (3) tyrosine 3 to 5 mol, valine 4 to 8 mol, leucine 2 to 12 mol, isoleucine 3 to 9 mol, arginine 0.1 to 5 mol, glutamic acid 0.1 to 4 mol, An amino acid composition comprising aspartic acid 0.1 to 5 mol, alanine 0.1 to 12 mol, proline 4 to 30 mol, lysine 5 to 11 mol, and phenylalanine 0.5 to 5 mol as an active ingredient, Endurance improver, fatigue inhibitor, and / or fatigue recovery agent, and (4) tyrosine 3-4 mol, valine 4-8 mol, leucine 2-12 mol, isoleucine 3-9 mol, arginine 0.1- 5 mol, glutamic acid 0.1-4 mol, aspartic acid 0.1-5 mol, alanine 0.1-12 mol, proline 4-30 mol, lysine 5-11 mol, phenylalanine 0.5- Mol,
  • the present invention includes (5) tyrosine 3.5 to 4 mol, valine 5 to 7 mol, leucine 6 to 8 mol, isoleucine 4 to 6 mol, arginine 3 to 5 mol, glutamic acid 3 to 5 mol, aspartic acid Endurance improver and fatigue comprising as an active ingredient an amino acid composition comprising 0.1 to 1 mol, alanine 6 to 8 mol, proline 15 to 20 mol, lysine 8 to 10 mol, and phenylalanine 3 to 5 mol An inhibitor and / or a fatigue recovery agent, and (6) tyrosine 3.8-4 mol, valine 5.8-6 mol, leucine 6.2-6.4 mol, isoleucine 4.5-4.7 mol Arginine 3.5 to 3.7 mol, Glutamic acid 3.2 to 3.4 mol, Aspartic acid 0.15 to 0.17 mol, Alanine 6.1 to 6.3 mol, Proline 18 to 19 mol, Lysine 8 .7 ⁇
  • An endurance improver comprising as an active ingredient an amino acid composition comprising 53 to 0.55 mol, histidine 2.6 to 2.8 mol, and tryptophan 2.2 to 2.4 mol, and A fatigue recovery agent is also included.
  • the tyrosine concentration is preferably 50 to 90%, more preferably 70 to 90%, still more preferably 75 to 85%, compared to the conventional wasp-derived amino acid composition (VAAM). Particularly preferred is about 80%, and the tyrosine concentration is preferably 2.4 to 4.3 mol% (3.5 to 6.3 wt%), more preferably 3.3 to 4.3 mol% (4 0.8-6.3 wt%), more preferably 3.6-4.1 mol% (5.2-5.9 wt%), and tyrosine is 0.05-0.065 mol.
  • tyrosine is about 3.9 mol (about 5.5 parts by weight)
  • valine is about 6.0 mol (about 5.6 parts by weight)
  • leucine is about 6.3 mol (about 6 parts by weight).
  • 0.5 parts by weight about 4.6 moles (about 4.8 parts by weight) of isoleucine, about 3.6 moles (about 5.0 parts by weight) of arginine, and about 3.3 moles (about 3.8 parts) of glutamic acid. Parts by weight), about 0.16 moles (about 0.22 parts by weight) of aspartic acid, about 6.3 moles (about 4.4 parts by weight) of alanine, and about 18.4 moles (about 16.8 parts by weight) of proline.
  • a suitable buffer, isotonic agent, etc. may be added as an injection and dissolved in sterilized distilled water.
  • the endurance improver, fatigue inhibitor, or fatigue recovery agent of the present invention can be made into appropriate dosage forms such as powders, granules, tablets, capsules, and liquids.
  • adjuvants commonly used in formulation such as excipients, binders, disintegrants, and lubricants, can be added.
  • excipients include starch, lactose, sucrose, methyl cellulose, carboxymethyl cellulose, sodium alginate, calcium hydrogen phosphate, synthetic aluminum silicate, microcrystalline cellulose, polyvinyl pyrrolidone (PVP), and hydroxypropyl starch (HPS).
  • binders there are starch, microcrystalline cellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (PVP), gum arabic powder, gelatin, glucose, sucrose and the like, or water / ethanol solutions thereof.
  • disintegrants include starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, microcrystalline cellulose, hydroxypropyl starch, and calcium phosphate.
  • lubricants carnauba wax, light anhydrous silicic acid, synthetic aluminum silicate, natural aluminum silicate, synthetic magnesium silicate, hardened oil, hardened vegetable oil derivative (Sterotex HM), sesame oil, white beeswax, titanium oxide, dry hydroxide
  • lubricants carnauba wax, light anhydrous silicic acid, synthetic aluminum silicate, natural aluminum silicate, synthetic magnesium silicate, hardened oil, hardened vegetable oil derivative (Sterotex HM), sesame oil, white beeswax, titanium oxide, dry hydroxide
  • Al gel stearic acid calcium stearate, magnesium stearate, talc, calcium hydrogen phosphate, sodium lauryl sulfate and the like.
  • the dose can be set very broadly. In general, it can be appropriately set in consideration of various factors such as the administration route and the age, weight, and symptoms of animals to be administered including humans.
  • the present invention is not limited to this, it is preferably 0.3 g to 8 g / kg / day, more preferably 0.4 g to 5 g / kg / day, still more preferably 0.5 g to 3 g / kg as a suitable active ingredient. / Day.
  • a 0.3-6.0 wt% solution preferably a 1.0-2.0 wt% solution
  • a 0.3 to 6.0% by weight solution can be administered at 100 to 400 ml, preferably 150 to 300 ml per dose.
  • the endurance improver, fatigue inhibitor, or fatigue recovery agent of the present invention can be administered either orally or parenterally (intramuscular, subcutaneous, intravenous, suppository, transdermal, etc.).
  • the endurance improver, fatigue inhibitor, or fatigue recovery agent of the present invention can be edible as it is, but can also be used as an additive to various foods.
  • the amino acid composition of the present invention can be dissolved in water to make a beverage.
  • other nutritional components such as water-soluble vitamins and taurine can be further added.
  • it can also be set as a drink by adding salts, such as sodium chloride, acids (acidulant), such as a citric acid, and / or other suitable flavors.
  • salts such as sodium chloride, acids (acidulant), such as a citric acid, and / or other suitable flavors.
  • a pH adjuster and a chelating agent can be further added.
  • the endurance improver, anti-fatigue agent, or fatigue recovery agent of the present invention is preferably administered continuously, and preferably administered for one week or longer.
  • each group contains a control, an aqueous solution of an amino acid composition derived from a wasp (VAAM aqueous solution), an aqueous solution of an amino acid composition derived from an wasp reduced to 80% of tyrosine (Tyr 80%), or An aqueous solution (Tyr20%) of a wasp-derived amino acid composition in which only tyrosine was reduced to 20% was orally administered.
  • VAAM aqueous solution an aqueous solution of an amino acid composition derived from a wasp
  • Tyr 80% aqueous solution of an amino acid composition derived from an wasp reduced to 80% of tyrosine
  • the swimming time was measured every week up to 5 ⁇ ⁇ week (5th week). On the day of measurement of the swimming time, the experimental sample was orally administered 30 minutes before the start of swimming.
  • Glucose CII-Test Wako (manufactured by Wako Pure Chemical Industries) is used to measure blood glucose levels
  • Determiner LA (manufactured by Kyowa Medex) is used to measure lactic acid levels
  • NEFA C-Test Wako (manufactured by Kyowa Medex Co., Ltd.). Wako Pure Chemical Industries, Ltd.) was used.
  • the measurement result of blood glucose level is shown in FIG. There was no significant difference in the blood glucose level of each group.
  • FIG. 5 shows the measurement result of the lactic acid level in the blood. Before administration and 30 minutes after administration (immediately before exercise), there was no significant difference in the lactic acid level in the blood of each group. Compared with the control group, the Tyr100% group and Tyr 80% group showed a significant decrease in lactic acid level immediately after exercise, and suppressed the increase in lactic acid associated with exercise.
  • FIG. 6 shows the measurement results of blood free fatty acid (NEFA) values.
  • NEFA blood free fatty acid
  • ketone hydroxylbutyric acid
  • Each group was divided into a non-exercise group and an exercise group (swimming) at 8 weeks (8th week) after the start of administration.
  • mice were dissected and the organ weights (liver, kidney, spleen, peri-testicular fat, gastrocnemius, quadriceps) were measured. Glycogen levels were also measured in the liver and gastrocnemius muscle. Glucose CII-Test Wako (Wako Pure Chemical Industries, Ltd.) was used for glycogen measurement.
  • the measurement results of the organ weight are shown in FIGS.
  • the Tyr 100% group showed a significant decrease in adipose tissue weight compared to the control group.
  • the Tyr100% group significantly increased the weight of the typhoid muscle and quadriceps muscle compared with the control group. There were no differences in other organs (liver, kidney, spleen).
  • the invention of the present application can be used as a medicine, health and health food, beverage, or feed that is useful for improving endurance, recovering from fatigue, preventing fatigue, and the like for sports athletes, manual workers, livestock, and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention vise à spécifier des composants d'acide aminé ou des concentrations de composants d'acide aminé, dans une composition d'acide aminé, qui sont efficaces pour l'amélioration de l'endurance physique, la prévention de la fatigue ou la récupération de la fatigue, et vise également à réduire la quantité de composant d'acide aminé ayant une solubilité médiocre dans une composition d'acide aminé. La tyrosine est tout d'abord identifiée comme étant un acide aminé qui contribue à l'amélioration de l'endurance physique. La concentration en tyrosine (qui a une solubilité médiocre dans l'eau) nécessaire à l'amélioration de l'endurance physique ou autre est ensuite étudiée. Il en résulte qu'une composition d'acide aminé ayant une solubilité élevée et d'excellentes propriétés améliorant l'endurance physique et autre peut être obtenue.
PCT/JP2009/067387 2008-10-06 2009-10-06 Agent d'amélioration de l'endurance physique, agent antifatigue ou agent de récupération de la fatigue comportant une composition d'acide aminé en tant qu'ingrédient actif Ceased WO2010041647A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN2009801394775A CN102170876B (zh) 2008-10-06 2009-10-06 含有氨基酸组合物作为有效成分的耐力提高剂、抗疲劳剂或疲劳恢复剂
HK12100054.9A HK1159507B (en) 2008-10-06 2009-10-06 Physical endurance improving agent, anti-fatigue agent or fatigue recovering agent comprising amino acid composition as active ingredient
JP2010532916A JPWO2010041647A1 (ja) 2008-10-06 2009-10-06 アミノ酸組成物を有効成分として含む持久力向上剤、疲労防止剤、又は疲労回復剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008-259678 2008-10-06
JP2008259678 2008-10-06

Publications (1)

Publication Number Publication Date
WO2010041647A1 true WO2010041647A1 (fr) 2010-04-15

Family

ID=42100597

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/067387 Ceased WO2010041647A1 (fr) 2008-10-06 2009-10-06 Agent d'amélioration de l'endurance physique, agent antifatigue ou agent de récupération de la fatigue comportant une composition d'acide aminé en tant qu'ingrédient actif

Country Status (3)

Country Link
JP (1) JPWO2010041647A1 (fr)
CN (1) CN102170876B (fr)
WO (1) WO2010041647A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016014007A (ja) * 2014-06-13 2016-01-28 花王株式会社 筋タンパク質合成シグナル活性化剤
US10413563B2 (en) * 2017-05-10 2019-09-17 Emerald Neuro-Recover, LLC Neurochemical wellness program
JP2020033269A (ja) * 2018-08-27 2020-03-05 味の素株式会社 脳機能改善用組成物
WO2020045612A1 (fr) * 2018-08-31 2020-03-05 味の素株式会社 AGENT AMÉLIORANT L'ENDURANCE INTERMITTENTE OU AGENT AUGMENTANT LE pH DU SANG
JP2023533617A (ja) * 2020-07-02 2023-08-03 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド 水分補給を促進するための製剤およびその使用方法
KR20250122526A (ko) 2022-12-20 2025-08-13 아지노모토 가부시키가이샤 간헐적 지구력 향상제

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311061A (zh) * 2014-05-31 2016-02-10 陈光健 一种具有创面修复作用的药物组合物及其制备方法和应用
CN105192810A (zh) * 2015-10-29 2015-12-30 常州亚当生物技术有限公司 一种复合氨基酸饮料及其制备方法、应用
CN105640995A (zh) * 2016-03-01 2016-06-08 四川好医生攀西药业有限责任公司 一种药物组合物及其应用
JP2017088616A (ja) * 2017-02-09 2017-05-25 株式会社東洋新薬 黒生姜含有組成物
JPWO2021200214A1 (fr) * 2020-04-03 2021-10-07
CN114786502A (zh) * 2020-04-03 2022-07-22 三菱瓦斯化学株式会社 肌肉增强剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03128318A (ja) * 1989-06-14 1991-05-31 Rikagaku Kenkyusho 筋力持続剤，滋養強壮剤，輸液用剤，栄養補給剤，疲労回復剤及び乳酸生成調節剤
WO2003011056A1 (fr) * 2001-07-31 2003-02-13 Ajinomoto Co., Inc. Compositions alimentaires ergogeniques

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2873497B2 (ja) * 1990-09-03 1999-03-24 理化学研究所 脂質代謝調節剤
JP4528925B2 (ja) * 2003-05-30 2010-08-25 独立行政法人理化学研究所 アミノ酸組成物及び補液
US20080114067A1 (en) * 2005-01-31 2008-05-15 Takanobu Yamamoto Composition for Recovery From or Prevention of Central Nervous System Fatigue
JP5764281B2 (ja) * 2006-06-08 2015-08-19 株式会社明治 血液流動性改善剤
CN101454000A (zh) * 2006-06-13 2009-06-10 明治乳业株式会社 含有氨基酸组合物的抗疲劳剂
NZ579189A (en) * 2007-02-28 2012-03-30 Meiji Co Ltd Casein amino acid mixture composition for promoting fat burning, improving endurance, reducing fatigue, supporting recovery from fatigue, obesity resistance and stress resistance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03128318A (ja) * 1989-06-14 1991-05-31 Rikagaku Kenkyusho 筋力持続剤，滋養強壮剤，輸液用剤，栄養補給剤，疲労回復剤及び乳酸生成調節剤
WO2003011056A1 (fr) * 2001-07-31 2003-02-13 Ajinomoto Co., Inc. Compositions alimentaires ergogeniques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AVRAHAM, Y. ET AL.: "Tyrosine improves appetite, cognition, and exercise tolerance in activity anorexia", MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, vol. 33, no. 12, 2001, pages 2104 - 2110 *
HIROMICHI KOBAYASHI: "Sport to Amino-san supplement", SHOKU NO KAGAKU, 1999, pages 93 - 88 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016014007A (ja) * 2014-06-13 2016-01-28 花王株式会社 筋タンパク質合成シグナル活性化剤
US10413563B2 (en) * 2017-05-10 2019-09-17 Emerald Neuro-Recover, LLC Neurochemical wellness program
JP2020033269A (ja) * 2018-08-27 2020-03-05 味の素株式会社 脳機能改善用組成物
JP7275499B2 (ja) 2018-08-27 2023-05-18 味の素株式会社 脳機能改善用組成物
WO2020045612A1 (fr) * 2018-08-31 2020-03-05 味の素株式会社 AGENT AMÉLIORANT L'ENDURANCE INTERMITTENTE OU AGENT AUGMENTANT LE pH DU SANG
US20210177793A1 (en) * 2018-08-31 2021-06-17 Ajinomoto Co., Inc. INTERMITTENT ENDURANCE CAPACITY IMPROVING AGENT OR BLOOD pH ELEVATING AGENT
JPWO2020045612A1 (ja) * 2018-08-31 2021-08-12 味の素株式会社 間欠的持久力向上剤または血中ｐＨ上昇剤
JP7264169B2 (ja) 2018-08-31 2023-04-25 味の素株式会社 間欠的持久力向上剤または血中ｐＨ上昇剤
US12220395B2 (en) * 2018-08-31 2025-02-11 Ajinomoto Co., Inc. Intermittent endurance capacity improving agent or blood pH elevating agent
JP2023533617A (ja) * 2020-07-02 2023-08-03 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド 水分補給を促進するための製剤およびその使用方法
EP4175662A4 (fr) * 2020-07-02 2024-07-17 University Of Florida Research Foundation, Incorporated Formulations pour favoriser l'hydratation et procédés d'utilisation associés
KR20250122526A (ko) 2022-12-20 2025-08-13 아지노모토 가부시키가이샤 간헐적 지구력 향상제

Also Published As

Publication number Publication date
JPWO2010041647A1 (ja) 2012-03-08
HK1159507A1 (en) 2012-08-03
CN102170876A (zh) 2011-08-31
CN102170876B (zh) 2013-12-04

Similar Documents

Publication Publication Date Title
WO2010041647A1 (fr) Agent d'amélioration de l'endurance physique, agent antifatigue ou agent de récupération de la fatigue comportant une composition d'acide aminé en tant qu'ingrédient actif
Rémond et al. Postprandial whole-body protein metabolism after a meat meal is influenced by chewing efficiency in elderly subjects
JP4528925B2 (ja) アミノ酸組成物及び補液
US20070286909A1 (en) Amino acid compositions
HUE032486T2 (en) An improved method for administering beta-hydroxy-beta-methylbutyrate (HMB)
TW201919601A (zh) 用於治療和高血氨症或肌肉耗損中之一者或兩者相關之肝疾病及失調之組合物及方法
CN111479580A (zh) 采用自噬诱发剂和高蛋白质的组合来诱发自噬的组合物和方法
JPWO2008149802A1 (ja) アンドログラホリドを有効成分とする抗疲労剤及び経口組成物
WO2015194447A1 (fr) Agent améliorant le métabolisme du glucose
JP2018517782A (ja) 相乗的飲料組成物
JP2010138170A (ja) 抗疲労組成物
US11331318B2 (en) Arterial oxygen saturation degree improver
EP1552826A1 (fr) Compositions d'acides amines destinees a ameliorer les fonctions centrales
CA2641675A1 (fr) Procede d'amelioration de l'administration orale d'acide alpha-lipoique
JPWO2015022962A1 (ja) 脂質代謝促進剤
JPWO2015022962A6 (ja) 脂質代謝促進剤
TW201912171A (zh) 戈氏副擬桿菌用於降低胰島素抗性及提升葡萄糖耐受性之用途
Soomro et al. Role of branched chain amino acids in the management of hepatic encephalopathy
JP5734134B2 (ja) 抗疲労用医薬組成物
HK1159507B (en) Physical endurance improving agent, anti-fatigue agent or fatigue recovering agent comprising amino acid composition as active ingredient
JPWO2003068215A1 (ja) ミトコンドリア病用薬剤
KR100523354B1 (ko) 지구성 운동시 피로억제 및 운동 수행 후 면역기능 향상을위한 약학적 조성물 또는 기능성 식품
JPWO2020080398A1 (ja) アルコール飲料摂取による悪酔い又は二日酔いの抑制剤
JP2011148769A (ja) 分枝鎖アミノ酸分解抑制剤
TW202009005A (zh) 具抗氧化活性之組合物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980139477.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09819181

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010532916

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09819181

Country of ref document: EP

Kind code of ref document: A1